74results about "Cationic antimicrobial peptides" patented technology

Peptides that bind with high affinity to oral cavity surfaces, such as tooth enamel, have been discovered. The peptides exhibit antibacterial and mineralizing abilities, and are useful in many aspects of oral care. The peptides include the amino acid sequence AKRHHGYKRKFH-SpSp. The peptides can be included in oral care compositions such as toothpastes and mouthwashes. The oral care compositions can be used in methods to treat or prevent diseases or conditions induced by acidophilic oral bacteria. Exemplary methods include reducing or preventing tooth decay or demineralization, biofilm or dental plaque formation, and / or bacterial adhesion to a tooth surface; and promoting mineralization of teeth surfaces.

The invention relates to an antibacterial peptide CnCATH as well as a coding gene and application thereof, and belongs to the technical field of biomedicine. The novel antibacterial peptide is extracted from sika deer bone marrow, and the amino acid sequence is as shown in SEQ ID NO. 2. The antibacterial peptide shows strong antibacterial activity on various microorganisms including gram-negative bacteria, gram-positive bacteria and fungi, the sterilization speed of the antibacterial peptide is obviously improved compared with that of traditional antibiotics, the bacterial strain is not prone to drug resistance, endotoxin can be further neutralized, and the concentration of the endotoxin can be further reduced. The novel sika deer-derived antibacterial peptide provided by the invention has the advantages of small molecular weight, simple artificial synthesis, low drug resistance tendency and high broad-spectrum bactericidal activity, and provides a new strategy for microbial anti-infection treatment and prevention and treatment of diseases caused by endotoxin.

The invention discloses a porcine beta-defensin-3 gene core promoter as well as a construction method and application thereof, and belongs to the technical field of gene engineering. The sequence of the core promoter is as shown in SEQ ID No.1, and the core promoter has remarkable promoter activity in porcine small intestine epithelial cells and can be regulated and controlled by nutrient substances sodium butyrate and glutamine. The invention also discloses a construction method for specifically amplifying the core promoter, which comprises the following steps: carrying out PCR (Polymerase Chain Reaction) amplification by taking porcine small intestine epithelial cell DNA (Deoxyribonucleic Acid) as a template, constructing a pMD-18T-pBD-3-P recombinant plasmid by taking upstream and downstream primers as shown in SEQ No.2-SEQ No.3, and amplifying by taking the recombinant plasmid as a template to obtain a core promoter fragment. The core promoter disclosed by the invention provides an excellent experimental system for researching a transcription regulation mechanism of the porcine beta-defensin-3 gene, the nutritional response characteristic of the core promoter provides a new platform for researching nutrition-immune interaction, and the core promoter has a wide application prospect in the field of healthy breeding of livestock and poultry.

The application discloses a kind of composition with immunoregulation and anti-aging function and preparation method thereof, and core component is marine collagen peptide, fusion polypeptide CPF-1, targeting senescent cell monoclonal antibody mAb Senolix, five gallate acyl glucose (PGG) and Hericium erinaceus polysaccharide.Fusion polypeptide CPF-1 is designed by domain fusion strategy, with collagen binding, immune activation and antibacterial function;Monoclonal antibody mAb Senolix targets the surface antigen p16^(INK4a) of senescent cell, and removes senescent cell by ADCC effect.The composition significantly improves immune cell activity, promotes collagen synthesis and reduces chronic inflammation through the synergistic effect of multiple components, and shows excellent immunoregulation and anti-aging effect in in vitro cell model and immunosuppressed mouse model, and can be used for developing immune enhancer, anti-aging drug or functional food.

The invention relates to an antimicrobial peptide consisting of the amino acid sequence: RX1WILX2WLRTWX3X4 wherein X1, X2, X3 and X4 are independently selected from K and R, and wherein each amino acid is independently in the L or D configuration, or a salt or solvate thereof. The use of said antimicrobial peptide in the treatment of an infection caused by Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts, as well as the use of said peptide as an antimicrobial agent for the prevention of contamination of an article or a living tissue by and / or for the decontamination of an article or a living tissue from Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts are further aspects of the invention.

The chimeric signal peptide for protein expression comprises an N region, a hydrophobic region, and a C region, wherein the N region and the C region are from the same signal peptide of a first protein, and the hydrophobic region is from the signal peptide of a second protein, and the first protein is different from the second protein. The first and second proteins can be independently selected from the group consisting of BM40, IL2, HA, insulin, CD33, IFNA2, IgGK leader, AZU, and SEAP.

Compositions are provided for the formulation of theta defensins and / or theta defensin analogs that are highly suitable for parenteral administration. Compositions are provided for the formulation of theta defensins and / or theta defensin analogs that are highly suitable for parenteral administration.SOLUTION: Such formulations provide the theta defensin and / or theta defensin analog in a slightly acidic buffer containing propylene glycol. Surprisingly, the inventors have found that such formulations increase the bioavailability of θ-defensins and / or θ-defensin analogues so provided by at least a factor of 10 compared to conventional isotonic saline solutions, and dramatically improve bioavailability in human subjects compared to animal models. The inventors have also found that such formulations advantageously exhibit low viscosity at high peptide concentrations, allowing reduced injection volumes and sterilization by simple filtration.SELECTED DRAWING: Figure 2

Peptides for use in systems that prevent the interaction of the FadA protein released from the Fusobacterium nucleatum (F. nucleatum) bacterium with E-cadherin, which has a carcinogenic effect, or the inhibition of the microorganism with antimicrobial agents and that will inhibit the carcinogenesis mechanisms of F. nucleatum infection and enable the development of therapeutic systems against infections that may occur due to the decreased immunity of patients undergoing cancer treatment with the use of peptides with anti-cancer and antimicrobial properties by developing ten peptides with FadA protein binding energy greater than −11.6 kcal / mol. Peptides with anticancer and antimicrobial properties allow the development of therapeutic systems to prevent F. nucleatum infection, to prevent cancer development after F. nucleatum infection, or to develop therapeutic systems against infections that occur due to the decreased immunity of cancer patients due to cancer treatment.

Antimicrobial modified defensin or defensin-like peptides, modified C-terminal fragments of a defensin or defensin-like peptides and nucleic acids encoding the same are disclosed. Compositions comprising the defensin variant peptides and methods of their use to control microbial infections of plants and vertebrate subjects as well as contamination of feedstuffs and foodstuffs are also disclosed.

Described herein is a bifunctional peptide, compositions comprising the same, and methods useful for treatment of peri-implant disease.

Broad spectrum antiviral peptides and composition including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting to viral resistance. The antiviral compositions are useful for treatment of diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, and the non-enveloped rhinovirus.

The present invention describes a branched peptide of formula (I), the use of the same as an antibacterial, and related pharmaceutical compositions or medical devices.

To provide hepcidin analogs with improved in vivo half-lives, and related pharmaceutical compositions and methods of use thereof.SOLUTION: The present invention relates generally to hepcidin analog peptides and methods of making and using the same. In certain embodiments, hepcidin analogs exhibit one or more hepcidin activities. In certain embodiments, the present invention is directed to hepcidin peptide analogs comprising one or more peptide subunits, wherein the peptide subunits form a cyclized structure via an intramolecular bond, e.g., an intramolecular disulfide bond. In certain embodiments, cyclized structures have increased potency and selectivity compared to non-cyclized hepcidin peptides and analogs thereof. In certain embodiments, the hepcidin analog peptides of the present invention exhibit an extended half-life compared to hepcidin or conventional hepcidin analogs when delivered orally.SELECTED DRAWING: None

Disclosed is an antimicrobial peptide comprising the sequence IGKX1FX2RIVX3RKX4RFLX5X6LVRPLX7 (SEQ ID NO: 7), wherein each of X1, X2, X3, X4, X5, X6, and X7 is an amino acid independently selected from the group consisting of E, K, R, L, I, V, F, A, W, V and P, preferably from the group consisting of E, K, R, L, I, V, F, A, W and V, more preferably from the group consisting of E, K, R, L, W and V. Optionally, one amino acid in this sequence selected from the group of L, V, F, A, I, W, Y or Q, with the exception of X1-X7, is replaced by another amino acid selected from said group or by P. Particularly preferred peptides are IGKEFKRIVERKWRFLRELVRPLR (SEQ ID NO: 2), IGKKFKRIVRRKKRFLRKLVRPLR (SEQ ID NO: 3), IGKEFKRIVERKWRFLRKLVRPLR (SEQ ID NO: 4), IGKEFLRIVERKWRFLRKLVRPLL (SEQ ID NO: 5) and IGKEFLRIVERKWRFLVKLVRPLL (SEQ ID NO: 6).

The present invention provides hepcidin analogs with improved in vivo half-lives, as well as related pharmaceutical compositions and methods of use. The present invention generally relates to hepcidin analog peptides and methods of making and using them. In certain embodiments, the hepcidin analogs exhibit one or more hepcidin activities. In certain embodiments, the present invention relates to hepcidin peptide analogs comprising one or more peptide subunits, which form a cyclized structure via an intramolecular bond, such as an intramolecular disulfide bond. In certain embodiments, the cyclized structure exhibits increased potency and selectivity compared to non-cyclized hepcidin peptides and analogs thereof. In certain embodiments, the hepcidin analog peptides of the present invention exhibit an extended half-life when delivered orally compared to hepcidin or conventional hepcidin analogs.

The present invention relates to the fragment-based synthesis of peptides, in particular the peptide LL37. In specific the present invention relates to a method for fragmented solid phase synthesis of an LL37 peptide of SEQ ID NO: 1, or a variant thereof, comprising providing a first fragment of LL37, or a variant thereof, coupled to a first resin solid support by a cleavable linker, providing at least one further side chain protected fragment of LL37 coupled to a second resin solid support, wherein the fragment-resin linker is acid labile, cleaving the further side chain protected fragment(s) from the second solid support without deprotecting the side chains, and sequentially coupling the first and further fragments to produce a peptide of SEQ ID NO: 1, or a variant thereof.

Disclosed herein are PEG-maximin H5 peptide conjugates and methods for using the same in the treatment or prevention of biofilms and biofouling.

The invention provides a site-specific mutagenesis vector and a use method thereof, and relates to the field of gene engineering in the biotechnological pharmaceutical industry, the vector contains BbsI restriction enzyme cutting sites except for a polyclone region, and site-specific mutagenesis comprises the steps of carrying out base mutation on the BbsI restriction enzyme cutting sites, removing the BbsI sites and keeping amino acid unchanged. According to the invention, a Golden gate method is adopted to construct the multi-copy vector, and a plurality of copies are directly assembled on a system in one step, so that the time is saved, and the tedious steps of multiple times of enzyme digestion and connection are omitted. According to the invention, a multi-copy vector is constructed in vitro, the copy number of the antibacterial peptide is increased, simultaneous expression of each unit is realized, and the expression quantity is improved. Meanwhile, the antibacterial peptide genes are connected in series by adopting a serial connection technology of the antibacterial peptide genes, so that the expression quantity of the antibacterial peptide is improved on the DNA level.

An isolated, non-naturally occurring cell penetrating peptide (CPP) comprising the amino acid sequence: RRSRTARAGRPGRNSSRPSAPR [SEQ ID NO: 1] and sequences having at least 60% similarity to SEQ ID NO: 1.

The present invention relates to peptides for treatment of skin diseases and skin conditions. In particular, the present invention relates to peptide for treatment of wounds and / or blisters in patients suffering from a skin disease or skin condition selected from the group consisting of blistering disease, a disease or condition characterized by excessive wound exudate, a disease or condition characterised by a dysregulated skin microbiome and scars.

The invention relates to a peptide that can be used as an alternative to existing antibiotics for the inhibition of pathogenic microorganisms and the treatment of infections due to these microorganisms, contributing to the prevention of resistance development arising from antibiotic use by reducing antibiotic use, is safer compared to human-derived natural peptides, has a very low toxicity compared to existing antimicrobial peptides, and also reducing tissue damage and side effects during infection by reducing inflammation due to microbial infections, also having the potential to regulate the immune system and immunomodulation, which will contribute to fight infections by influencing the activation and function of immune cells.

The application discloses a pig beta-defensin-3 gene core promoter and a construction method and application thereof, and belongs to the technical field of genetic engineering. The sequence of the core promoter is shown as SEQ ID No. 1, the core promoter has significant promoter activity in pig small intestinal epithelial cells, and can be regulated by nutrients such as sodium butyrate and glutamine. The application also discloses a construction method for specifically amplifying the core promoter, which comprises the following steps: performing PCR amplification by taking pig small intestinal epithelial cell DNA as a template, taking the upstream primer and the downstream primer shown as SEQ No. 2-SEQ No. 3 as the primer, constructing a pMD-18T-pBD-3-P recombinant plasmid, and taking the recombinant plasmid as a template to amplify a core promoter fragment. The core promoter provides an excellent experimental system for studying the transcriptional regulation mechanism of the pig beta-defensin-3 gene, the nutrient response characteristics provide a new platform for studying the interaction between nutrition and immunity, and the core promoter has a wide application prospect in the field of healthy breeding of livestock and poultry.

A method for producing a SARS-CoV-2 virus-like particle-based protein subunit vaccine. The method comprises creating a fusion protein by combining a DNA sequence encoding an iLOV protein with a DNA sequence encoding a peptide linker and a cleavage site for enterokinase protease and a DNA sequence encoding a Receptor Binding Domain (RBD) of the SARS-CoV-2 viral spike protein. The RBD protein is attached to a “Spy Tag” peptide. The peptide linker cleavage site DNA sequence is between the iLOV protein DNA sequence and either the SARS-CoV-2 viral protein DNA sequence or the “Spy Tag” peptide DNA sequence. The DNA sequence encoding the fusion protein is introduced into a P. pastoris host to form transformants. At least one optimal recombinant is identified from the transformants using fluorescence to detect optimal expression levels of the SARS-CoV-2 viral protein. The SARS-CoV-2 viral protein is isolated from the fusion protein by cleaving the iLOV protein and linker sequences from the target protein. The RBD sequence can be mutated to represent RBD variants or homologous sequences or improve expression and alter its glycosylation pattern. The RBD sequence can belong to any virus within the coronavirus family.

The present application provides a tuberculosis vaccine based on bovine beta defensin 5 and its application in preventing tuberculosis, which comprises a fusion protein of tuberculosis AH antigen and bovine beta defensin 5 or a coding sequence thereof. The present application fuses and expresses Ag85A and HspX, which are surface dominant antigens of Mycobacterium tuberculosis, and an optimized sequence of bovine beta defensin 5, and then purifies the protein to mix with poly I:C to prepare a fusion protein vaccine AHB-P. Or the coding sequence of the fusion gene is optimized and then connected to a vector pVAX1 to prepare a fusion DNA vaccine pVAX1-AHB. The respiratory mucosa of mice is immunized with the two fusion vaccines, and it is proved that the two fusion vaccines can enhance the body's resistance to tuberculosis infection.

The present invention provides a covalent conjugate. The conjugate includes an antibody or antibody derivative, at least two LL37-derived polypeptides, and a payload. The antibody or antibody derivative targets a cell that has phosphatidylserine in its outer leaflet. The payload includes: a small molecule cytotoxic drug of less than 3 kDa, or a plurality thereof; or a peptide or protein of less than 100 kDa. Uses and methods of using these covalent conjugates are also provided, related to enhancing delivery of the antibody / derivative or the payload, e.g. to enhance therapeutic or diagnostic effectiveness.

Described is an antibacterial protein S2200 which has specific antibacterial activity against Staphylococci including Staphylococcus aureus. More specifically, described is antibacterial protein S2200 specific for Staphylococci including Staphylococcus aureus, which has the ability to specifically lyse Staphylococci including Staphylococcus aureus and has the amino acid sequence represented by SEQ ID NO: 1; and a pharmaceutical composition for the treatment of infections caused by Staphylococci including Staphylococcus aureus, containing as an active ingredient antibacterial protein S2200 specific for Staphylococci including Staphylococcus aureus.

The present disclosure relates to RNA and other polynucleotides encoding antigens, which can be used in vaccine compositions. In some examples, the RNA or polynucleotides further encode an adjuvant, such as a cathelicidin or fragment thereof. The present disclosure also relates to the use of the RNA, polynucleotides, or compositions in methods of inducing an immune response in a subject.

The invention relates to the field of molecular vaccinology, in particular to a vaccine aiming at severe malaria, and further relates to a multi-epitope fusion antigen vaccine derived from plasmodium falciparum STEVOR protein as well as preparation and application of the multi-epitope fusion antigen vaccine. The multi-epitope fusion antigen vaccine contains at least two amino acid fragments in a B cell epitope, a CD4 and T cell epitope and a CD8 and T cell epitope. The MEFA vaccine targeting STEVOR protein SC structural domain conservative immunodominant epitopes has broad spectrum, can realize 97.15% global HLA coverage rate through the conservative epitopes, can synchronously induce IgG antibody and CD4 + / CD8 + T cell response, is safe, has no toxicity / sensitization, and has good in-vivo and in-vitro stability (the mammalian half-life period gt; further, the strain is used for inducing wide immune response for resisting severe malaria, and is suitable for large-scale production of an escherichia coli or yeast expression system.

The present invention relates to peptides for the treatment of skin diseases and skin conditions. In particular, the present invention relates to peptides for use in the treatment of wounds and / or vesicles in a patient suffering from a skin disease or skin condition selected from the group consisting of vesicular diseases, diseases or conditions characterized by excessive wound exudate, diseases or conditions characterized by skin microbiome disorders and scars.